...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Translational research: the journal of laboratory and clinical medicine >Influence of high-flux hemodialysis and hemodiafiltration on serum C-terminal agrin fragment levels in end-stage renal disease patients
【24h】

Influence of high-flux hemodialysis and hemodiafiltration on serum C-terminal agrin fragment levels in end-stage renal disease patients

机译：高通量血液透析和血液透析滤过对终末期肾脏病患者血清C末端凝集素片段水平的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

C-terminal agrin fragment (CAF, 22 kDa) has been shown to be a promising new rapid biomarker for kidney function. This study evaluated the influence of hemodialysis (HD) and hemodiafiltration (HDF) treatment on serum CAF concentrations in patients with end-stage renal disease (ESRD). A total of 36 patients with ESRD undergoing chronic HD/HDF treatment were enrolled (21 high-flux-HD/Fx60 membrane, 7 high-flux-HD/Elisio 19H membrane, and 8 HDF/Elisio19H membrane). On a midweek session, blood samples were obtained before, at halftime, and post-treatment. Dialysate samples were obtained 4 times during treatment. Serum and dialysate CAF, cystatin C, urea, and creatinine concentrations were measured. Reduction ratios (RRs), total solute removal, overall dialytic clearance, and instantaneous dialytic clearance at halftime were calculated and compared. Although HD/Elisio19H and HDF/Elisio19H treatments significantly reduced CAF concentrations (RR 46.6 +/- 9.1% and 57.6 +/- 11.7%, respectively, P = 0.018 and P = 0.001), HD/Fx60 treatment did not remove CAF from serum (RR 2.4 +/- 15.4%, P= 0.25), there was no relevant CAF detection in dialysate. In the HD/Fx60 group, the RR of CAF was significantly lower compared with cystatin C, urea, and creatinine, in which significant removal was detected (37.9 +/- 14.8%, 65.0 +/- 10.7%, and 56.0 +/- 9.8%, respectively, P < 0.001). CAF is a new biomarker for kidney function whose serum concentration is not influenced by conventional high-flux HD using Fx60 membrane. It might therefore represent a promising dialysis-independent biomarker for evaluation of kidney function, for example, in acute kidney failure.
机译：C端凝集素片段（CAF，22 kDa）已被证明是有前途的肾脏功能快速生物标记。这项研究评估了血液透析（HD）和血液透析滤过（HDF）治疗对终末期肾病（ESRD）患者血清CAF浓度的影响。总共纳入了36位接受慢性HD / HDF治疗的ESRD患者（21例高通量HD / Fx60膜，7例高通量HD / Elisio 19H膜和8例HDF / Elisio19H膜）。在一周中的会议中，在治疗前，治疗中和治疗后采集血样。在处理过程中获得了4次透析液样品。测量血清和透析液CAF，胱抑素C，尿素和肌酐的浓度。计算并比较还原率（RRs），总溶质去除量，总透析清除率和半时的瞬时透析清除率。尽管HD / Elisio19H和HDF / Elisio19H治疗显着降低了CAF浓度（RR分别为46.6 +/- 9.1％和57.6 +/- 11.7％，P = 0.018和P = 0.001），但HD / Fx60处理并未从血清中去除CAF。 （RR 2.4 +/- 15.4％，P = 0.25），透析液中没有相关的CAF检测。在HD / Fx60组中，与半胱氨酸蛋白酶抑制剂C，尿素和肌酐相比，CAF的RR显着降低，其中可检出率显着降低（37.9 +/- 14.8％，65.0 +/- 10.7％和56.0 +/-分别为9.8％，P <0.001）。 CAF是一种新的肾脏功能生物标志物，其血清浓度不受使用Fx60膜的常规高通量HD的影响。因此，它可能代表一种有前途的不依赖透析的生物标志物，用于评估肾功能，例如急性肾衰竭。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号